On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
ThursdayFeb 22, 2018 3:55 pm

QualityStocksNewsBreaks – Teewinot Life Sciences Produces Cannabinoids through Patent-protected CANNSYNTHESIS Technology

Cannabinoid-based pharmaceuticals company Teewinot Life Sciencess employs its patent-protected CANNSYNTHESIS® technology to biosynthesize cannabinoids for the large-scale manufacture of pharmaceutically pure cannabinoids. An article discussing the company’s technology reads: “Apart from THC and CBD, many of the 111 or so cannabinoids found in the cannabis plant are produced in minute quantities. Production by extraction is thus prohibitively costly, meaning that most cannabinoids have not been available for research and therapeutic applications. The CANNSYNTHESIS® platform has changed that paradigm, however, since it allows for the efficient production of cannabinoids in kilogram quantities. Teewinot’s CANNSYNTHESIS® has taken the production of cannabinoids from…

Continue Reading

FridayFeb 16, 2018 12:11 pm

QualityStocksNewsBreaks – Teewinot Life Sciences Lowers Production Cost of Clinical-Grade Cannabinoids with Proprietary Synthetic Biology Technology

Teewinot Life Sciences is on a mission to cut costs of cannabinoid production while approaching the process like a pharmaceutical company, not as a cannabis firm. An article discussing the company reads: “Teewinot Life Sciences is a Tampa, Florida-based global biopharmaceutical company focused on cannabinoid clinical development utilizing patented and proprietary synthetic biology and biocatalysis technology. Its strategy involves the production and use of cannabinoid molecules. The goal of the company is to produce, at lower cost, consistent and pure cannabinoids that it believes can be used to develop superior human therapies.” To view the full article, visit http://ibn.fm/8EvOn Let…

Continue Reading

FridayFeb 09, 2018 3:49 pm

Teewinot Life Sciences Corporation is Producing Cannabinoids without Touching the Plant

Producing cannabinoids through biosynthesis CANNSYNTHESIS® platform has capacity to scale up Revenues from out-licensing technology For the half a billion or so who suffer from one type or another of diabetes, biosynthesis offers a lifeline. For it is through biosynthesis that much of the world’s insulin is produced. Insulin regulates the metamorphosis of fats and protein and, importantly, allows the cells in the muscles, fat and liver to absorb glucose from the blood. When the body does not produce enough insulin nor use the insulin it produces efficiently, blood sugar levels may rise dangerously. However, biosynthesis, a mid-twentieth century technology,…

Continue Reading

TuesdayFeb 06, 2018 1:30 pm

Teewinot Life Sciences’ Patented Biosynthetic Tech Cuts Costs and Produces Clinical-Grade Cannabinoids

Company’s IP portfolio, including proprietary technology and biosynthetic methods, features seven U.S. patents and patent filings in numerous other key countries around the world Eliminating the high costs of cultivating plants, Teewinot Life Sciences Corporation delivers pure, consistent pharmaceutical-grade cannabinoids Company’s goal is to cut costs and approach cannabinoid production like a pharmaceutical company, not as a cannabis firm Teewinot Life Sciences Corporation has an advantage in consistently producing pure, clinical-grade cannabinoids with its patented biosynthetic technology. The results eliminate the watering and electrical costs of traditional plant cultivation, as well as the variances in quality. Instead, its method offers…

Continue Reading

MondayFeb 05, 2018 12:12 pm

QualityStocksNewsBreaks – Teewinot Life Sciences Subsidiary Granted New Broad Claiming U.S. Patent

Cannabinoid-based pharmaceuticals company Teewinot Life Sciences, along with its wholly-owned Irish subsidiary, Teewinot Technologies, Ltd., this morning announced the grant of U.S. Patent No. 9,879,292. The newly granted patent covers biosynthetic production of cannabinoids and cannabinoid analogs. "We are happy to announce the continued expansion of our valuable patent portfolio. Our technology platform enables standardized and cost-effective manufacturing for the expanding category of cannabinoid-based pharmaceuticals. Teewinot is currently in the process of identifying lead pre-clinical and clinical indications and are the premier, integrated biopharmaceutical company in this space with multiple US patents issued and a verifiable, scalable, plant-free biological manufacturing…

Continue Reading

FridayFeb 02, 2018 12:30 pm

QualityStocksNewsBreaks – Teewinot Life Sciences Positioned as Major Player in the Manufacture, Delivery of Cannabinoids Products

Cannabinoid-based pharmaceuticals company Teewinot Life Sciences Corporation has created patent protected methods to produce exact cannabinoid molecules called CANNSYNTHESIS®. An article discussing the company reads: “To protect this invaluable asset, Teewinot has taken aggressive intellectual property protection actions and filed patent applications in key countries around the world. Teewinot has created an exceptional combination of cutting edge scientific research on cannabinoids and an aggressive intellectual property portfolio to develop new and improved patient therapies and build significant value.” To view the full article, visit http://ibn.fm/LJ21T Let us hear your thoughts: Teewinot Life Sciences Message Board About Teewinot Life Sciences Corporation…

Continue Reading

WednesdayJan 31, 2018 2:10 pm

Teewinot Life Sciences Corporation: At the Vanguard of Biopharmaceutical Cannabinoid Therapeutics

Global medicinal cannabinoid market to exceed $55 billion by 2025 Teewinot has created patent protected methods to produce exact cannabinoid molecules called CANNSYNTHESIS® Efficient cost-effective methods reduce production time and increase purity There is indisputable scientific evidence of the curative effects of cannabinoids, and specialty biopharmaceutical companies are positioning to capitalize on the explosive growth expected in the cannabinoid-derived pharmaceutical market. In a report that may be substantially underestimated, the global medical cannabinoid market is expected to exceed $55 billion by 2025 (http://ibn.fm/stG53). However, the discovery of the human endocannabinoid system dramatically changed both the understanding and the vast potential…

Continue Reading

MondayJan 22, 2018 12:40 pm

QualityStocksNewsBreaks – Teewinot Life Sciences Corporation Awarded Broad US Patent

Cannabinoid-based pharmaceuticals company Teewinot Life Sciences Corporation this morning announced that it has been granted U.S. Patent No. 9,861,609. Per the update, the newly-issued patent has broad claims to biosynthetic methods for the pharmaceutical manufacture of cannabinoids and cannabinoid analogs. “With the grant of the '609 patent, Teewinot has now secured six U.S. patents covering processes for the manufacture of naturally-occurring cannabinoids, cannabinoid prodrugs and analogs using both biocatalysis and synthetic biology,” Dr. Richard Peet, Teewinot’s executive vice president and co-inventor of the new patent, stated in the news release. “Teewinot has filed patent applications in key countries around the…

Continue Reading

TuesdayJan 16, 2018 4:30 pm

Teewinot Life Sciences is “One to Watch”

Holds 6 U.S. patents covering biosynthesis of cannabinoids, including first U.S. issued patent to create water-soluble cannabinoids Aggressively seeking intellectual property patent protection in key countries worldwide Able to manufacture kilogram quantities of 18 naturally occurring cannabinoids through biosynthetic processes Canadian subsidiary holds controlled substances license from Health Canada Teewinot Life Sciences is an international biopharmaceutical company focused on the use of synthetic biology and advanced formulation for the production and implementation of cannabinoid-based therapies. Headquartered in Tampa, Florida, Teewinot is a global leader in the formulation, manufacturing and delivery of products containing cannabinoids, cannabinoid prodrugs, and cannabinoid analogs. The…

Continue Reading

Market Basics

New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

The Basics

Newsletter Publishers

Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.


Public Companies

Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

Get Covered